Profilo
Elisabeth Whiting joined AnorMED in February 2001 and is responsible for the company's corporate strategic planning as well as all aspects of internal and external communications and investor relations.
Ms. Whiting has over 10 years of management experience in the biotechnology field including scientific research, financial and scientific communications and business development.
Prior to joining AnorMED, Ms. Whiting was Director, Investor Relations and Corporate Communications at Stressgen Biotechnologies Inc. Ms. Whiting holds a Masters of Science degree from the University of Ottawa.
Precedenti posizioni note di Elisabeth Whiting
| Società | Posizione | Fine |
|---|---|---|
AnorMED, Inc.
 AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Public Communications Contact | 09/11/2006 |
Formazione di Elisabeth Whiting
| University of Ottawa | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
AnorMED, Inc.
AnorMED, Inc. Pharmaceuticals: MajorHealth Technology AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. | Health Technology |
- Borsa valori
- Insiders
- Elisabeth Whiting